About Freya Biosciences
Freya Biosciences is a company based in Copenhagen (Denmark) founded in 2023 by Johan E T Van Hylckama Vlieg, Colleen Acosta, and Thomas Gundelund Rasmussen. It operates as a HealthTech. Freya Biosciences has raised $49.8 million across 2 funding rounds from investors including Gates Foundation, Danmarks Eksport og Investeringsfond and Sofinnova Partners. The company has 16 employees as of November 30, 2024. Freya Biosciences offers products and services including FB101, IVF Support Therapy, and Endometriosis Treatment. Freya Biosciences operates in a competitive market with competitors including Aphrodite Health, health mavens and ELAINE studies, among others.
- Headquarter Copenhagen, Denmark
- Employees 16 as on 30 Nov, 2024
- Founders Johan E T Van Hylckama Vlieg, Colleen Acosta, Thomas Gundelund Rasmussen
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
$-11.77 M (USD)-152as on Dec 31, 2023
-
EBITDA
$-12.57 M (USD)-121as on Dec 31, 2023
-
Total Equity Funding
$49.8 M (USD)
in 2 rounds
-
Latest Funding Round
$11.8 M (USD), Series A
Nov 19, 2024
-
Investors
Gates Foundation
& 7 more
-
Employee Count
16
as on Nov 30, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Freya Biosciences
Freya Biosciences offers a comprehensive portfolio of products and services, including FB101, IVF Support Therapy, and Endometriosis Treatment. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapeutic solution targeting vaginal dysbiosis for women.
Therapy addressing dysbiosis for improved IVF outcomes.
Treatment targeting dysbiosis linked to endometriosis infertility.
Funding Insights of Freya Biosciences
Freya Biosciences has successfully raised a total of $49.8M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $11.8 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $11.8M
-
First Round
First Round
(12 Dec 2023)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2024 | Amount | Series A - Freya Biosciences | Valuation | Gates Foundation , Danmarks Eksport og Investeringsfond |
|
| Dec, 2023 | Amount | Series A - Freya Biosciences | Valuation | Sofinnova Partners , OMX Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Freya Biosciences
Freya Biosciences has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, Danmarks Eksport og Investeringsfond and Sofinnova Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Founded Year | Domain | Location | |
|
Venture capital investments are made in transformative biotech companies by OMX Ventures.
|
Founded Year | Domain | Location | |
|
Angelini Ventures is focused on investing in BioTech and Digital Health.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Freya Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Freya Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Freya Biosciences Comparisons
Competitors of Freya Biosciences
Freya Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aphrodite Health, health mavens and ELAINE studies, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Psychedelic medicines for women are developed by this CRO.
|
|
| domain | founded_year | HQ Location |
Offers clinical development services as a CRO focused on drugs for women's health.
|
|
| domain | founded_year | HQ Location |
Conducts research and trials for breast cancer drugs like lasofoxifene.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Freya Biosciences
Frequently Asked Questions about Freya Biosciences
When was Freya Biosciences founded?
Freya Biosciences was founded in 2023.
Where is Freya Biosciences located?
Freya Biosciences is headquartered in Copenhagen, Denmark.
Who is the current CEO of Freya Biosciences?
Colleen Acosta is the current CEO of Freya Biosciences. They have also founded this company.
Is Freya Biosciences a funded company?
Freya Biosciences is a funded company, having raised a total of $49.8M across 2 funding rounds to date. The company's 1st funding round was a Series A of $38M, raised on Dec 12, 2023.
How many employees does Freya Biosciences have?
As of Nov 30, 2024, the latest employee count at Freya Biosciences is 16.
What does Freya Biosciences do?
Freya Biosciences is engaged in creating innovative microbial immunotherapies to address chronic inflammation and immune dysregulation in womens reproductive health. Solutions are developed for conditions such as infertility, endometriosis, and preterm birth. The company is supported by a data-driven platform integrating clinical trial results and extensive microbiome and immune marker data. Research and therapeutic development are targeted at improving outcomes in IVF, natural conception, and other reproductive system disorders. Partnerships, such as with Boston IVF, are established to advance clinical studies in the US.
Who are the top competitors of Freya Biosciences?
Freya Biosciences's top competitors include Aphrodite Health, health mavens and ELAINE studies.
What products or services does Freya Biosciences offer?
Freya Biosciences offers FB101, IVF Support Therapy, and Endometriosis Treatment.
Who are Freya Biosciences's investors?
Freya Biosciences has 8 investors. Key investors include Gates Foundation, Danmarks Eksport og Investeringsfond, Sofinnova Partners, OMX Ventures, and Angelini Ventures.